means for determining binding between said biochemical material and said biomolecule;

whereby at least one analysis to determine a presence of a marker, analyte thereof, or a biochemical material specific thereto, is carried out on a sample.

29.   Polyclonal antibodies produced against a marker sequence ID selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof in at least one animal host.

30.   An antibody that specifically binds a biopolymer including a marker selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof.

33.   A process for identifying therapeutic avenues related to a disease state comprising:

conducting an analysis as provided by the kit of claim 18; and

interacting with a biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof;

whereby therapeutic avenues are developed.

34.   The process for identifying therapeutic avenues related to a disease state in accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof.

38. A process for regulating a disease state by controlling the presence or absence of a

biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or

at least one analyte thereof.

REMARKS

The foregoing Supplemental Preliminary Amendment is made so as to further bring this

application into conformance with Rules 37 CFR §1.821 - 1.825. No new matter is added.

Examination on the merits is respectfully requested.

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Page 46, line 9, replace "(R)SNLDEDIIAEENIVSR(S)" with --SEQ ID NO: 1--.

Page 46, line 11, replace "(R)EGVQKEDIPPADLSDQVPDTESETR(I)" with --SEQ ID NO:

2--.

Page 46, line 13, replace "(K)VTIKPAPETEKRPQDAK(N)" with --SEQ ID NO: 3--.

IN THE CLAIMS: